Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Azacitidine Maintenance in TP53-Mutant AML/MDS Post-Transplant
NCT07094464Phase 1Active, not recruiting
- Sponsor
- Daihong Liu
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Daihong Liu. Primary endpoint: Disease relapse at 1 year. Started Jun 2025; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07094464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094464.